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Abstract
Rabies virus causes lethal brain infection in about 61000 people per year. Each year, tens of thousands of people receive
anti-rabies prophylaxis with plasma-derived immunoglobulins and vaccine soon after exposure. Anti-rabies immunoglob-
ulins are however expensive and have limited availability. VHH are the smallest antigen-binding functional fragments of
camelid heavy chain antibodies, also called Nanobodies. The therapeutic potential of anti-rabies VHH was examined in a
mouse model using intranasal challenge with a lethal dose of rabies virus. Anti-rabies VHH were administered directly into
the brain or systemically, by intraperitoneal injection, 24 hours after virus challenge. Anti-rabies VHH were able to
significantly prolong survival or even completely rescue mice from disease. The therapeutic effect depended on the dose,
affinity and brain and plasma half-life of the VHH construct. Increasing the affinity by combining two VHH with a glycine-
serine linker into bivalent or biparatopic constructs, increased the neutralizing potency to the picomolar range. Upon direct
intracerebral administration, a dose as low as 33 mg of the biparatopic Rab-E8/H7 was still able to establish an anti-rabies
effect. The effect of systemic treatment was significantly improved by increasing the half-life of Rab-E8/H7 through linkage
with a third VHH targeted against albumin. Intraperitoneal treatment with 1.5 mg (2505 IU, 1 ml) of anti-albumin Rab-E8/H7
prolonged the median survival time from 9 to 15 days and completely rescued 43% of mice. For comparison, intraperitoneal
treatment with the highest available dose of human anti-rabies immunoglobulins (65 mg, 111 IU, 1 ml) only prolonged
survival by 2 days, without rescue. Overall, the therapeutic benefit seemed well correlated with the time of brain exposure
and the plasma half-life of the used VHH construct. These results, together with the ease-of-production and superior
thermal stability, render anti-rabies VHH into valuable candidates for development of alternative post exposure treatment
drugs against rabies.
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Introduction
Rabies virus (Familia Rhabdoviridae, Genus Lyssavirus) is a
model neurotropic RNA virus, which causes an aggressive and
lethal infection in the brain of humans and mammals [1]. Once
the virus enters peripheral nerves or neurons, the virus replicates
quickly in the neuronal cytoplasm and progeny virus is transported
through the neuronal network by crossing tight interneuronal
synapses [2,3].
Nanobodies (a trade-name by Ablynx) or VHH are the smallest
functional portions (15 kDa) of heavy chain-only antibodies
naturally occurring in Camelidae, and represent the antigen-
binding variable domain. VHH consist of a single antigen-binding
domain that does not require hydrophobic interaction with a light
chain, leading to high solubility, physicochemical stability and
high-yield production in Escherichia coli or yeast. The single
domain nature and the small size of VHH allow easy formatting
by genetic fusion into multimeric constructs with multiple
specificities [4–6].
Previously, we developed a number of rabies virus-specific
VHH directed against the rabies virus spike glycoprotein G [7]. In
vitro, these VHH were fully able to neutralize the rabies virus
infectivity in neuroblastoma and baby hamster kidney cells-21
(BHK-21) and could neutralize a wide spectrum of Lyssavirus
species. The neutralizing potency increased massively when two
VHH were combined with a glycine-serine linker into bivalent or
biparatopic constructs [7].
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Other research groups have developed antiviral VHH against a
number of viruses [6]. For foot-and-mouth disease virus, rotavirus,
respiratory syncytial virus and influenza virus, specific antiviral
VHH were also tested in animal models. For these viruses,
preventive treatment with VHH could delay or prevent disease
upon challenge. In general, administration of VHH after infection
had a limited effect on viral load or animal-to-animal transmission
[8–11]. In the case of rotavirus, preventive treatment with VHH
and continued administration until day 7 of infection was able to
completely protect pigs from diarrhea, resulting in an asymptom-
atic infection and the development of a humoral immune response
[11].
Anti-rabies antibodies are able to protect mice upon preventive
administration and offer partial protection against disease and
mortality upon early administration in a post exposure setting [12–
14]. Antibody fragments, such as VHH or F(ab9)2, lack Fc
domains, which render them incapable of exerting Fc effector
functions, such as complement activation or interaction with Fc
receptors on phagocytes. To what extent these effector functions
contribute in control and clearance of infection, seems to depend
on the virus [15]. In the case of influenza A virus, Fc effector
function are not necessary for protection, whereas in the case of
human immunodeficiency virus, the loss of Fcc-receptor binding
function greatly increased the risk of infection upon pre-exposure
treatment [16,17].
F(ab9)2 fragments, obtained after pepsin digestion of whole
antibodies, have reduced activity against rabies virus in mice [14].
Still, F(ab9)2 fragments derived from equine immunoglobulins are
used in post exposure prophylaxis in humans as a cheaper
substitute for human anti-rabies immunglobulins [18]. Recom-
mended doses for equine F(ab9)2 (40 IU/kg) are two-fold higher
than for human rabies immunoglobulins (20 IU/kg).
To date, little is known concerning the potential of VHH to
neutralize rabies virus in vivo or to treat rabies virus infection.
Viral receptors present in vivo are most likely different from the
receptors responsible for virus uptake in cell lines [19]. Previously,
Dietzschold et al. [20] found that the neutralizing potency of
conventional antibodies determined in cells lines can differ
substantially from their in vivo potency. Since VHH lack the Fc
fragment of conventional antibodies, their in vivo antiviral activity
might be compromised. A recent paper by the group of Boruah
et al. [21] showed that pentameric constructs of anti-rabies VHH
were able to partially neutralize rabies virus when co-injected with
virus in the hindleg of mice. Constructs were composed of five
homologous single domain antibody fragments fused to a coiled-
coil peptide. The used dose was however relatively low (0.2–
1.6 IU/ml). Also, the effect of treatment after virus challenge, as
would occur under natural circumstances, was not examined.
In the current work we wanted to further explore the protective
effect of anti-rabies VHH in vitro and in vivo using constructs with
high antiviral potencies. Two homologous (bivalent) or heterolo-
gous (biparatopic) VHH were genetically fused with glycine-serine
linkers to increase potency. Moreover, the in vivo circulating half-
life of these constructs was extended by adding a third VHH
targeted against albumin.
The aims of this study were to (1) compare the neutralizing
potency of distinct monovalent, bivalent, biparatopic and half-life
extended anti-rabies VHH both in vitro and in vivo, (2) assess the
efficacy of anti-rabies VHH in delaying infection and disease, or
even to rescue mice, by post exposure treatment after lethal
intranasal virus challenge and (3) correlate the clinical outcome
with the pharmacokinetic characteristics, including the total brain
exposure, of anti-viral VHH.
Results
1. Characterisation of the mouse rabies model
In order to test the in vivo efficacy of different anti-rabies VHH,
a mouse model reflecting the neurological late stage of rabies
disease was set-up and characterised. In a first series of
experiments, disease symptoms and viral kinetics in the brain
were assessed after intranasal inoculation of rabies virus. This
route of inoculation allows the virus to directly access the brain via
the olfactory epithelium, either through the olfactory nerve or the
trigeminal nerve [22]. First disease signs appear at 7.160.67 days
post inoculation (DPI) and severe neurological disease, requiring
euthanasia, is observed at 8.360.88 days. Mortality is 100%.
Virus spread through the brain over time was monitored by
measuring the change in viral RNA load in the brain by
quantitative real-time PCR (qRT-PCR) from 1 to 7 DPI, at
which time clinical disease becomes obvious (Figure 1). Already at
1 DPI, virus can be detected in the olfactory bulbs (of 3/10 mice),
with all mice being positive from 2 DPI onwards. The virus
spreads from the frontal to the distal parts of the brain in a matter
of days. In the cerebrum and diencephalon, viral RNA can be
detected as soon as 2 DPI (in 4/7 mice) and from 3 DPI onwards
in all mice. In the hindbrain and cerebellum, RNA can be
detected as soon as 3 DPI (in 2/7 mice) and in all mice from 4 DPI
onwards. Peak viral RNA levels (DCt$25) are observed from 6
DPI onwards, which precedes the occurrence of severe neurolog-
ical disease (score$6) by 1 day. In conclusion, the intranasal
inoculation of rabies virus provides an excellent infection model to
study the efficacy of antiviral treatment in the brain. In contrast to
intracerebral inoculation, it leaves the brain mechanically intact,
and yields a highly reproducible brain infection and disease
outcome with little variation in the median survival time.
2. Neutralizing potency of different anti-rabies VHH
constructs in vitro and in vivo
2.1. Co-administration of virus and VHH. In previous
work, we described the generation of different anti-rabies
glycoprotein G VHH constructs [7]. The virus-neutralization
capacity of different monovalent, bivalent, biparatopic and half-
life extended VHH constructs in vitro and in mice was compared
(Table 1). Low doses of anti-rabies VHH (0.12 mg, 1 IU) were pre-
incubated for 30 minutes at 37uC with the rabies virus, prior to
administration to either BHK-21 cells or to different virus-
receptive body compartments of the mouse (intranasal IN,
intracerebral IC and intramuscular IM).
All VHH constructs showed in vitro virus neutralization with
IC50 values ranging from 0.1–15 nM whereas an irrelevant VHH
construct was not active, confirming the specificity of the
neutralization effect. The in vitro neutralization experiments
showed that overall the potency of the VHH constructs increased
significantly from monovalent to bivalent, and finally to the
biparatopic constructs, with the latter having a comparable or
higher potency as compared to the reference rabies monoclonal
antibody.
In vivo, most bivalent and biparatopic constructs offered full
protection in all the body compartments tested. Monovalent VHH
could partially protect mice when the mix was administered
intranasally, but not when administered directly into the brain.
Remarkably, both monovalent and bivalent Rab-C12 VHH, while
highly neutralizing in vitro, protected less well than other VHH in
vivo. The biparatopic Rab-E8/H7 proved most potent in vitro
and in vivo, and was thus selected for further in vivo studies.
Addition of a third VHH (anti-human serum albumin) to Rab-E8/
H7, to enable a longer circulating half-life, did not impact the in
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vivo neutralizing potency, despite of a limited reduction of the
neutralizing potency in vitro (from 230000 IU/mM to 54388 IU/
mM).
In addition, the neutralizing potency of Rab-E8/H7 was further
investigated by determination of the viral load in the brain after
co-administration of the VHH and the virus. Figure 2 shows that
Rab-E8/H7 VHH efficiently inhibits the infectivity of rabies virus
in the brain, as no viral antigen could be detected and only
minimal levels of viral RNA at 7 DPI. The viral RNA load was
significantly lower compared to that in the brain of control mice
treated with an irrelevant VHH (p,0.001, t-test). In conclusion,
most bivalent and biparatopic anti-rabies VHH could completely
protect mice from disease upon inoculation of a pre-incubated mix
of VHH and a lethal dose of rabies virus in different body
compartments.
2.2. Pre-exposure administration of anti-rabies VHH. In
addition to the co-administration experiments, the most potent
rabies VHH, Rab-E8/H7 was tested for efficacy upon preventive
treatment. Pre-exposure treatment with a low dose of Rab E8/H7
(0.12 mg,1 IU) applied in the target organ (brain, IC) was followed
by virus challenge in the nose 24 hours after VHH treatment.
Complete protection was obtained against later IN virus challenge
(p,0.01, Log Rank test, Bonferroni post-test). This indicates that a
sufficiently high level of VHH remains present in the brain after
one day, and diffuses from the site of injection, to neutralise the
rabies virus upon brain entry via the nose (data not shown).
3. Post exposure treatment by direct intracerebral
administration of Rab-E8/H7
3.1. Administration of increasing doses at day one after
virus inoculation. To determine the minimal effective dose to
obtain protection against virus-induced mortality, mice were
treated in two independent experiments with different doses of
Rab-E8/H7 administered directly to the brain at one day after
virus challenge. In a first experiment, mice were treated with 1 mg
(4.63 IU), 10 mg (46.3 IU) or 100 mg (463 IU) at 24 hours after
virus inoculation (Figure 3A). Treatment with 1 mg of Rab-E8/H7
gave no significant delay in the median survival time compared to
animals treated with irrelevant VHH (9 days). A non-significant
effect was observed at a dose of 10 mg Rab-E8/H7 and significant
protection at a dose of 100 mg (p,0.01). To determine the
effective dose more precisely, a second experiment was performed
using two extra doses between 10 and 100 mg (Figure 3B).
Significant protection was observed starting from a dose of
33 mg (p,0.01 for 33 mg, 67 mg and 100 mg, Log-Rank test,
Bonferroni post-test). One third to more than half of the mice that
were treated with a dose of 33 mg or higher survived the infection.
There was no straightforward dose-response relationship in the
second experiment, as the 33 mg dose performed better than the
67 and 100 mg doses. This inconsistency was probably due to
experimental variation.
The antiviral effect of Rab-E8/H7 was further confirmed by
monitoring the spread of the virus to the posterior parts of the
brain by qRT-PCR (Figure 4). To this end, mice were treated
24 hours after intranasal virus inoculation by intracerebral
injection of 100 mg Rab-E8/H7 (463 IU) or irrelevant VHH.
Control mice were mock-treated with irrelevant VHH. Rab-E8/
H7 VHH-treated mice had no symptoms at day 7, whereas mock-
treated mice all presented serious nervous system disease
symptoms at this time point. Figure 4A shows that Rab-E8/H7
treatment had significantly reduced the spread of the virus from
the frontal to the posterior parts of the brain at day 7 after virus
inoculation (t-test, ** p,0.01 for olfactory bulbs and cerebrum/
diencephalon, *** p,0.0001 for hindbrain/cerebellum).
The long-term antiviral effect of intracerebrally injected Rab-
E8/H7 (treatment before virus challenge: 0.12 mg, 1 IU or after:
100 mg, 463 IU) was also examined in survivor mice. Figure 4B
shows the residual viral RNA load in the whole brain of survivor
mice at the convalescent phase of infection (day 35). The survivor
mice, which were treated either one day before or one day after
virus inoculation, had only minimal amounts of viral RNA (DCt
562.9) in the brain at 35 DPI (*** p,0.0001), which demonstrates
that they had successfully overcome the acute infection. Mice
treated with an irrelevant VHH had to be euthanized around day
7–9 of infection and always contained high levels of viral RNA in
the brain (DCt$28).
3.2. Administration at increasing time points after virus
inoculation. Given the protective nature of Rab-E8/H7 VHH
treatment when given 1 day post-exposure, follow-up experiments
were designed to elucidate the time-course of protection by Rab-
E8/H7. Mice were treated with an intracerebral dose of 100 mg
(463 IU) anti-rabies VHH at 1, 3 or 5 days after intranasal virus
inoculation. The protective effect of Rab-E8/H7 VHH dimin-
ished progressively when treatment was initiated at later stages of
infection (Figure 5). Median survival times were 13, 11 and 10.5
days upon starting Rab-E8/H7 VHH treatment at respectively
day 1, 3 and 5 post virus inoculation, compared to a median
survival time of 9 days in mock-treated mice. The prolongation of
Figure 1. Virus spread in the mouse brain following intranasal rabies virus inoculation. The graph presents the profile of viral RNA in
different parts of the brain (indicated in the left photo) upon intranasal inoculation of 102.5 CCID50/mouse. Groups of mice (n = 7–10) were intranasally
inoculated with rabies virus and sacrificed at various time points post inoculation (DPI). Viral loads were determined by qRT-PCR.
doi:10.1371/journal.pone.0109367.g001
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the median survival time was significant for treatment at day 1 or 3
(p,0.01, Log-Rank test, Bonferroni post-test), but not for
treatment at day 5. Thus, 3 DPI was identified as the latest
treatment time point to result in significant protection.
In two previous experiments (Figure 3A and B), 43–71% of
mice treated IC with 100 mg Rab-E8/H7 at 1 DPI survived. In the
third experiment (Figure 5), no mouse survived, albeit the median
survival time was still significantly prolonged. This experimental
variation may be explained because of small variations in the site
of intracerebral injection.
4. Pharmacokinetic characteristics of anti-rabies VHH
A pharmacokinetic experiment was designed to determine the
plasma and brain exposure following a single IP administration of
Rab-E8/H7. In this experiment, Rab-E8/H7 was compared with
a trivalent form of this VHH containing and extra anti-albumin
VHH. Addition of this VHH is supposed to increase the half-life in
circulation by binding to serum albumin. Both VHHs were
administered in equimolar doses (5 mg Rab-E8/H7-ALB and
10 mg Rab-E8/H7). Serum versus time concentration profiles
displayed a monophasic pharmacokinetic profile for both VHH
constructs, but with an obvious rapid decline for Rab-E8/H7,
Figure 2. Co-administration of anti-rabies Rab-E8/H7 and virus directly in the brain efficiently inhibits virus infection. Mice were
inoculated intracerebrally with a mix of rabies virus and 0.12 mg (1 IU) anti-rabies Rab-E8/H7 (A) or irrelevant VHH (B) and euthanized 7 days later. The
anti-rabies VHH-treated mice were protected from disease, whereas all the mock-treated mice developed severe nervous disease. The pictures
represent an immunofluorescence staining for viral nucleocapsid in the brain tissue. No viral antigens were visible in the brain of anti-rabies VHH-
treated mice (A), whereas green fluorescent spots indicate the abundant spread of virus in the brain of mock-treated mice (B). The graph (C) presents
the viral RNA load in the brains of different groups. Viral loads were significantly different between groups treated with Rab-E8/H7 and irrelevant
control VHH, between Rab-E8/H7 and uninfected controls and between irrelevant control VHH and uninfected controls (*** p,0.01).
doi:10.1371/journal.pone.0109367.g002
Figure 3. Dose-dependent efficacy of anti-rabies Rab-E8/H7 upon intracerebral post-exposure treatment at one day after intranasal
virus inoculation. Two independent experiments were performed. In the first experiment (A), doses of 1, 10 and 100 mg Rab-E8/H7 were tested and
in the second experiment (B), two additional doses of 33 mg and 67 mg were included. Significant protection was observed starting from a dose of
33 mg (p,0.01). One third to more than half of the mice that were treated at this or a higher dose survived the infection.
doi:10.1371/journal.pone.0109367.g003
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which is likely explained by rapid renal filtration (Figure 6).
Table 2 shows an overview of the mean calculated pharmacoki-
netic parameter estimates. Mean serum levels peaked at 0.08 h for
Rab-E8/H7 and at 4 h for Rab-E8/H7-ALB, confirming the half-
life extension (HLE) by addition of an anti-albumin VHH. We
therefore refer to this VHH as HLE Rab-E8/H7. Maximum
average brain levels were attained respectively at 0.5 h and 8 h
after dose administration, revealing a fairly rapid influx into brain,
which is indicative of a fast equilibrium between the blood and the
brain. Due to the albumin-binding capacity of HLE Rab-E8/H7,
a substantially higher systemic exposure (approximately hundred-
fold upon dose normalization) was attained for this half-life
extended VHH. Similarly to what was seen in the blood, the brain
was exposed to markedly higher VHH concentrations after dosing
with the HLE Rab-E8/H7. Elimination of the VHH from the
brain followed the same exponential disposition as in serum with
no apparent accumulation in the brain. This was observed for
both VHH constructs although slopes were steeper for the Rab-
E8/H7 because of higher clearance rates. When differences in
average systemic exposure were accounted for, both VHH
constructs displayed a similar mean ‘‘area under the curve
(AUC)’’-based brain/serum ratio of approximately 0.1%, despite
their differences in size and clearance rates. Also, mean brain/
serum concentration ratios stayed fairly constant over time
(Figure 7).
5. Post exposure treatment by systemic administration of
anti-rabies VHH with or without half-life extension
In an effort to determine whether systemic administration of our
anti-rabies VHH could also be protective, Rab E8/H7, both with
and without the introduction of a half-life extension (HLE)
module, was administered systemically one day after virus
inoculation.
Figure 4. Viral RNA load in the brain after anti-rabies Rab-E8/H7 treatment. (A) Mice were treated with Rab-E8/H7 (100 mg) by intracerebral
injection (IC) 24 hours after intranasal virus inoculation and sacrificed at 7 DPI to assess the viral RNA loads in different brain parts. Rab-E8/H7 VHH
treatment significantly reduced the spread of the virus from the front to the posterior parts of the brain (t-test, ** p,0.01, *** p,0.0001). (B) Mice
were treated with Rab-E8/H7 at 24 hours before (0.12 mg) or after (100 mg) intranasal virus inoculation. Control mice were mock-treated with
irrelevant VHH before virus inoculation. Viral RNA loads were measured at 35 DPI in the brain of survivor mice. Four out of five survivor mice, treated
after the virus inoculation, showed residual traces of viral RNA in the brain (DCt 562.9; *** p,0.0001). These mice had however never developed
signs of disease. All mock-treated mice had to be euthanized at 7–9 DPI, because of serious disease, which coincided with high viral RNA loads in their
brains (DCt$28).
doi:10.1371/journal.pone.0109367.g004
Figure 5. Post-exposure treatment by intracerebral injection at different time points of infection. Mice were treated with a single dose
of 100 mg (463 IU) Rab-E8/H7 at increasing time points of infection. The protective effect of anti-rabies VHH diminished progressively when treatment
was initiated at later stages of infection.
doi:10.1371/journal.pone.0109367.g005
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Mice that were treated by intraperitoneal injection with the
non-HLE Rab-E8/H7 VHH at 24 hours after intranasal virus
inoculation all developed disease and had to be euthanized (four
independent experiments; n = 7 mice per treatment group).
Nevertheless, administration of 10 mg (46300 IU) Rab-E8/H7,
but not 2 or 5 mg (9260 and 23150 IU, respectively), consistently
prolonged the median survival time by one day in all experiments
(p,0.05, Log-Rank test, Bonferroni post-test) (data not shown).
Compared to conventional antibodies, VHH have a short
plasma half-life (t1/2 Rab-E8/H7= 1.16 h). To assess the efficacy
of the HLE Rab-E8/H7 (t1/2 = 30.5 h), mice were treated by
intraperitoneal injection with an equimolar dose (15 mg,
25050 IU) or lower doses (5 mg, 8350 IU and 1.5 mg, 2505 IU)
of HLE Rab-E8/H7 at 24 hours after virus inoculation (Figure 8).
Half-life extension of Rab-E8/H7 strongly enhanced the protec-
tive effect against rabies virus-induced mortality. In comparison to
a one-day survival benefit seen with systemically delivered Rab-
E8/H7, the introduction of half-life extension into the Rab-E8/
H7 VHH improved median survival time by several weeks and
resulted in a high percentage of animals being completed
protected from lethal rabies challenge. This effect was significant
(p,0.001) for all doses and dose-dependent on overall survival (3/
7, 4/7 and 5/7 mice surviving, respectively) and median survival
time (20 d, 26 d and .26 d, respectively).
Based on the pharmacokinetic studies, the enhanced efficacy
and potency of the HLE Rab-E8/H7 can likely be explained by
higher brain exposure secondary to prolonged plasma exposure,
rather than to enhanced brain uptake.
In order to benchmark the efficacy seen with the HLE Rab-E8/
H7 VHH, similar experiments were conducted using commer-
cially available human rabies immunoglobulins (RIG) purified
from plasma of vaccinated human donors (Imogam, Sanofi
Pasteur SA, Lyon, France). Intraperitoneal treatment with the
maximal feasible dose of human RIG (1 ml intraperitoneally,
65 mg (111 IU)/mouse) was able to prolong the median survival
time by two days (p,0.05) (Figure 9). All mice still developed
serious neurological disease. The used dose of immunoglobulins
was 308 times higher than the prescribed dose for humans
(5550 IU/kg compared to 20 IU/kg) and represented the highest
feasible dose which could be administered to mice, respecting a
maximum IP injection volume of 1 ml.
Discussion
In this study, the antiviral effect of different anti-rabies VHH
constructs, targeted against the surface glycoprotein of the rabies
virus, was examined in a brain infection model in mice.
Monovalent, bivalent, biparatopic and half-life extended anti-
rabies VHH were first compared in vitro. Then, a step-wise
approach was used for extending the in vitro neutralisation results
to in vivo neutralisation, starting with a pre-exposure setting and
then testing the VHH in a prophylactic-therapeutic setting. Pre-
exposure treatment and virus-VHH co-administration were
primarily performed to proof the concept in a model with the
highest chance on success.
Despite the absence of Fc effector functions and the small size,
bivalent and biparatopic anti-rabies VHH are able to significantly
prolong survival or even completely rescue mice from disease. The
therapeutic effect depends on the time of treatment, dose, affinity,
brain and plasma half-life of the VHH construct.
Figure 6. Mean brain and serum concentration of Rab-E8/H7 and HLE Rab-E8/H7. Individual brain (circles) and serum (triangles)
concentrations and mean values (lines) of HLE Rab-E8/H7 (A) and Rab-E8/H7 (B) upon intraperitoneal injection of 5 mg HLE Rab-E8/H7 or 10 mg Rab-
E8/H7.
doi:10.1371/journal.pone.0109367.g006
Table 2. Overview of average pharmacokinetic parameter values.
Rab-E8/H7 HLE Rab-E8/H7
Parameter Serum Brain tissue Serum Brain tissue
Cmax (mg/mL) 162 0.23 539 0.241
Tmax (h) 0.08 0.50 4 8
t1/2 (h) 1.16 2.06 30.5 41.7
AUCinfinity (h*mg/mL) 493 0.58 24613 26
AUCinfinity/DOSE (h*mg/mL/mg) 0.0493 0.000058 4.93 0.0052
Values were estimated by non-compartmental analysis (sparse sampling, WinNonLin version 6.3, Phoenix Pharsight) for Rab-E8/H7 and HLE Rab-E8/H7 VHH in the serum
and brain tissue. Brain concentrations were normalized for a theoretical brain weight of 0.5 g per animal and a density of 1 g/ml was assumed).
doi:10.1371/journal.pone.0109367.t002
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Increasing the affinity by combining two VHH with a glycine-
serine linker into bivalent or biparatopic constructs, increased the
in vitro neutralizing potency to the picomolar range. The potency
of the different biparatopic constructs seemed to be higher than
that of the monovalent or bivalent VHH, which has also been
reported for other VHH directed against membrane receptors,
such as CXCR4 and EGFR, where conformational changes play a
role in the receptor activity [23,24,24]. The inhibitory effect of the
anti-rabies VHH might be due to steric hindrance, blocking the
viral glycoprotein G and cell receptor interactions, or impairment
of conformational changes in the G protein. Typically, biparatopic
VHH are better in preventing conformational changes. However,
the precise mechanism of VHH-mediated virus neutralisation
remains unknown.
At day one of virus infection, direct intracerebral administration
of the biparatopic Rab-E8/H7 at a dose as low as 33 mg was able
to establish a significant anti-rabies effect. This is remarkable since
the brain is extremely sensitive to infection and, in essence, only
one infectious virus particle is sufficient to induce lethal infection in
the absence of immunity [22].
Surprisingly, both monovalent and bivalent Rab-C12 VHH
were highly neutralizing in vitro, but protected less well in vivo.
Previously, we found that Rab-C12 recognizes a different epitope
than Rab-E8 and Rab-H7 [7]. We did not map epitopes, but
possibly the Rab-C12 epitope is less important for neutralisation in
vivo. Correspondingly, Dietzschold et al. [20] already described
that the neutralizing potency of antibodies can differ significantly
in vitro and in vivo. Possibly, the virus uses different receptors for
binding and uptake in vitro than in vivo.
Boruah et al. [21] reported that their pentavalent anti-rabies
VHH constructs were able to partially (40–50%) protect mice
against infection upon co-administration with virus in the hindleg.
Our results confirm their obervations, albeit that both our
monovalent and bivalent/biparatopic VHH constructs offered
complete protection upon co-administration.
Obviously, when sufficient amounts of VHH are introduced in
the brain at an early phase of infection (day 1), the further spread
of virus slows down to such an extent that complete rescue of mice
becomes feasible. Most likely, in survivor mice, the viral load never
reached the critical threshold to induce disease. In our experience,
Figure 8. Post-exposure treatment with anti-rabies Rab-E8/H7 with or without half-life extension (HLE). Half-life extension was
accomplished by adding a third anti-albumin VHH to Rab-E8/H7. Mice were treated intraperitoneally 24 hours after intranasal virus inoculation. The
clinical effect of Rab-E8/H7 was significantly improved by the half-life extension. The median survival time was prolonged by six to more than 26 days
(p,0.01), depending on the dose. More than 70% of the mice were completely protected against disease upon treatment with 15 mg HLE Rab-E8/
H7.
doi:10.1371/journal.pone.0109367.g008
Figure 7. Mean brain/serum concentration ratio. Mean brain/serum concentration ratio over time for HLE Rab-E8/H7 and Rab-E8/H7 upon
intraperitoneal injection of 5 mg HLE Rab-E8/H7 or 10 mg Rab-E8/H7 in mice.
doi:10.1371/journal.pone.0109367.g007
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a viral RNA load corresponding with a DCt of 28 or higher is
associated with the appearance of severe nervous system disease. A
delay in the build-up of virus, probably allows the immune
response to kick in and clear out or control the virus infection.
Indeed, upon post exposure treatment, survivor mice still
harboured small amounts of residual virus in their brain
(Figure 4A), but appeared in perfect health and had mounted
neutralizing antibodies in their blood (data not shown).
The efficacy of post exposure treatment diminishes progressively
when initiated at advanced stages of infection, varying from
significant protection (treatment at day 1) to no protection
(treatment at day 5) (Figure 5). At day 1, the spread of the
infection is still limited to neurons of the olfactory bulbs (Figure 1),
which agrees with previous studies [22,25]. At this early stage,
treatment can still prevent or delay spread to the rest of the brain.
At later stages, the virus has spread over larger parts of the brain.
We assume that anti-rabies VHH are able to intercept intercellular
virus spread, but can not diminish or clear out intracellular virus,
which limits the effect of VHH treatment at more advanced stages
of infection.
Compared to direct intracerebral treatment (33 mg), much
higher doses (10 mg) are needed to delay disease or protect mice
upon systemic treatment. The relative weaker performance of
systemic treatment can easily be explained by the fact that only a
small fraction of Rab-E8/H7 eventually reaches the brain.
Our pharmacokinetic data on systemic administration support
that the therapeutic benefit depends on the time of brain exposure
and the plasma half-life of the used VHH construct. Indeed, half-
life extension (HLE) of Rab-E8/H7, by adding a third VHH
targeting serum albumin, considerably improved the therapeutic
effect. Systemic administration of HLE Rab-E8/H7 resulted in a
prolonged survival of at least six days and complete protection
from disease in part of the mice (43–71%) in a dose-dependent
manner (Figure 8). Upon intraperitoneal administration, the brain
level of Rab-E8/H7 peaked 0.5 h after injection and Rab-E8/H7
was almost completely cleared from the brain within one day,
whereas HLE Rab-E8/H7 peaked 8 h after injection and
remained clearly detectable for ten days. This agrees with the
delay in disease onset with one day for Rab-E8/H7 and with six
days for HLE RabE8/H7.
The enhanced exposure in the brain of HLE Rab-E8/H7 seems
mainly due to the prolonged retention in the systemic circulation.
We found no evidence for active blood-brain barrier crossing with
the tested (HLE) anti-rabies VHH, as the brain levels followed the
systemic exposure. The brain levels of (HLE) VHH represented
0.1% the plasma levels suggesting a limited diffusion of anti-rabies
VHH to the brain, corresponding with distribution data also
described for antibodies [26,27]. It has been reported that certain
VHH, directed against glial fibrillary acidic protein, that contain
many positively charged residues, show enhanced crossing of the
blood brain barrier, presumably via an adsorption-mediated
uptake mechanism [28]. In this respect, it should be noted that
the VHH building blocks of Rab-E8/H7 each have isoelectric
point (pI) values around 7 and hence are neutrally charged. Our
pharmacokinetic results do not indicate that the rabies VHH
constructs used in our study can cross the blood-brain barrier to a
higher extent than reported for antibodies, despite their smaller
size. Modification of VHH by adding blood-brain barrier targeting
peptides might be an interesting future strategy to increase the
therapeutic potential [29].
For comparison, intraperitoneal treatment with the highest
available dose of human rabies immunoglobulins (RIG, Imogam,
65 mg, 111 IU, 1 ml) only prolonged survival by two days,
without rescue (Figure 9). The applied dose of RIG corresponded
to the highest volume of Imogam which could be administered to
mice and was about 308 times higher than the dose used in
humans. Treatment with HLE Rab-E8/H7 (1.5 mg, 2505 IU/
mouse) was more effective than treatment with RIG, probably due
to the higher neutralizing dose achieved with HLE Rab-E8/H7.
Still, it should be noted that HLE Rab-E8/H7 has a shorter
plasma half-life (30.5 h) than human immunoglobulins (8 days) in
mice [30].
The current work is presented as a proof-of-concept study,
without direct translation for clinical development. Still, we think
that HLE anti-rabies VHH have the potential to be used as an
alternative to RIG or monoclonal antibodies to provide passive
immunity after risk exposure. Of course, further validation in
animal models and trials in humans are needed to enforce this, as
the current study design and animal model does not allow
validation of VHH for post exposure prophylaxis in humans.
Rabies virus-exposed patients are currently treated with RIG
and vaccine soon after exposure [31]. Patients receive RIG and
vaccine on day 0 and additional vaccine shots in the following
weeks. The rationale is that patients need continued protection by
anti-rabies antibodies starting as soon as possible after exposure.
First protection is offered by passively acquired antibodies (RIG),
which are then gradually replaced by vaccine-induced antibodies.
Active antibodies are first mounted between day 7 and 14 [32], so
passively acquired antibodies need to bridge the immunity gap
between day 0 and 7–14. We believe that anti-albumin VHH can
easily be dosed to provide sufficient passive immunity for the first
7–14 days after exposure in humans. Indeed, the albumin-binding
Figure 9. Post-exposure treatment with human anti-rabies immunoglobulins (Imogam). Mice were treated intraperitoneally with 65 mg
(111 IU, 1 ml) of human rabies immunoglobulins at 24 hours after intranasal virus inoculation in two independent experiments (A and B). The median
survival time was prolonged by 2 days, but all mice developed serious nervous disease, requiring euthanasia.
doi:10.1371/journal.pone.0109367.g009
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VHH used in our study is known to have a longer plasma half-life
(10–20 days) in humans than in mice, which bodes well for the
potential use of the anti-rabies HLE Rab-E8/H7 VHH in humans
[33]. Importantly, the systemic levels of RIG obtained at the
recommended dose (20 IU/ml) remain remarkably low (0.01–
0.50 IU/ml) in humans [32], which is why the WHO recom-
mends to infiltrate RIG as much as possible locally in or around
the infected wound. In our experience, most RIG are administered
systemically, not at least because the bite wound is often localized
in a small body extremity, such as the nose or a finger, which does
not allow injection of a large volume (risk of compartment
syndrome). Interestingly, VHH can easily be concentrated to a
small volume which is better suited for injection in small body
parts.
These results provide evidence for the possible use of anti-rabies
VHH as valuable candidates for the development of alternative
post exposure treatment drugs for rabies. The ease of production
and high thermal stability of VHH are important advantages over
the currently used anti-rabies immunoglobulins. A further increase
of the half-life [34], blood-brain barrier crossing properties [28]
and/or brain delivery of systemically administered anti-rabies
VHH might further improve the therapeutic applicability of anti-
rabies virus VHH.
Materials and Methods
VHH and antibody
VHH directed against the rabies virus glycoprotein G were
generated previously [7]. Briefly, llamas were vaccinated with the
inactivated rabies Human Diploid Cell Vaccine (HDCV, Sanofi,
France) and RNA was extracted from peripheral blood lympho-
cytes. VHH genes were amplified from a cDNA library. Anti-
rabies virus VHH were selected by panning phage libraries on
plates coated with the native G protein. For the generation of
multivalent VHH constructs, monovalent VHH were genetically
fused into dimeric VHH constructs using flexible glycine-serine
(GS) linkers [8]. Bivalent VHH contained two identical VHH
monomer clones, whereas biparatopic VHH contained two
different VHH clones. RSV117, a bivalent respiratory syncytial
virus (RSV)-specific VHH, was used as a negative irrelevant
control VHH. The Rab-E8/H7 VHH was genetically fused with a
VHH directed against human serum albumin to extend the half-
life using a GS linker, resulting in HLE-Rab-E8/H7. The activity
of the resulting HLE Rab-E8/H7 VHH was tested in the virus-
neutralization assay to confirm that the fusion did not impact the
rabies neutralization. For initial characterization, all VHH were
produced with C-terminal cMyc-His6 tags in Eschericha coli. For
subsequent in vivo experiments Rab-E8/H7 and HLE Rab-E8/
H7 were recloned to Pichia pastoris expression vectors for
production in X-33 strain as tag-less proteins. All VHH were
purified to endotoxin levels ,5 EU/mg.
Human rabies immunoglobulins (HRIG) (Imogam, Sanofi
Pasteur SA, Lyon, France) are gammaglobulins purified from
plasma of vaccinated human donors.
Virus
Challenge Virus Standard (CVS)-11 is a virulent classical rabies
virus obtained from the American Type Culture Collection
(ATCC reference VR959) and was grown in baby hamster kidney
(BHK)-21 cells (Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH, Braunschweig, Germany). For virus inocu-
lation in mice, a dose of 102.5 50% cell culture infectious doses
(CCID50) of CVS-11 was used.
Virus-neutralization in vitro
The virus-neutralizing potency was titrated with the rapid
fluorescent focus inhibition test (RFFIT) according to the Manual
of Diagnostic Tests and Vaccines for Terrestrial Animals (Office
International des Epizooties, 2008). Briefly, a standard dose of
virus was pre-incubated with serially diluted VHH/antibody for
90 min at 37uC. BHK-21 cells were then added to the mix and co-
incubated for 24 hours. Infected BHK-21 cells were stained with
fluorescent anti-nucleocapsid antibody and foci of infected cells
were counted under the fluorescence microscope. The dilution
that yielded 50% inhibition of infected foci was determined. The
neutralizing potency is expressed in international units (IU)/ml in
reference to ‘‘The Second International Standard for Anti-Rabies
Immunoglobulin’’, purchased from the United Kingdom National
Institute for Biological Standards and Control.
Rabies ELISA
The Platelia TM Rabies II Kit from Bio-Rad (Cat number:
3551180) was used for assessing functional activity of the different
anti-rabies VHH constructs. A dilution series (in R6 buffer
provided with the kit) of the anti-rabies VHH was incubated on
the wells precoated with rabies virus glycoprotein for 1 h at 37uC.
After washing, bound VHH was incubated for 1 h at 37uC with
anti-VHH antibodies (in house produced, R345 rabbit anti-VHH
polyclonal antibodies, 1/2500) followed by an incubation with an
anti-rabbit-HRP antibody (BETHYL, Cat A120-201P, 1/1000)
for 1 h at 37uC. TMB (es(HS)TMB, Pierce) substrate was added
and incubated in the dark at room temperature, the reaction was
stopped after 30 min by addition of 1 M HCl. Read-out was done
at 450–620 nm.
Mouse inoculation experiments
Six-to-eight weeks old female Swiss outbred mice (Charles
River, France) were used in all experimental procedures. The
experimental procedures were approved by the local ethical
committee of the institute (advice nu 070515-05). Mice were kept
in filter top cages, water and feed were provided ad libitum and
exposed to a natural day/night light cycle. The intracranial (IC),
intranasal (IN) and intraperitoneal (IP) inoculation procedures are
described in detail by Rosseels et al. [35]. For IC, IN and IP
injection volumes of respectively 20, 25 and 1000 ml were used.
The intranasal inoculation of rabies virus is an excellent
technique to study antiviral treatment in the brain, since it leaves
the brain mechanically intact, in contrast to intracerebral
inoculation, and yields a highly reproducible brain infection and
disease outcome with little variation in the median survival time
[35]. This inoculation route has been used before for the
evaluation of post exposure prophylaxis of rabies in mice [14].
Prior to inoculation with virus or VHH, mice were briefly
anesthetized using isoflurane gas (IsoFlo, Abbott laboratories Ltd.,
Queenborough, Kent, United Kingdom).
Determination of viral kinetics in the brain
The viral RNA load was determined using real-time reverse
transcriptase polymerase chain reaction (RT-qPCR), as described
by Suin et al. [36], in the whole brain, or in the olfactory bulbs,
mid (cerebrum and diencephalon) and anterior (hindbrain and
cerebellum) parts of the brain. Primers recognize the nucleocapsid
region of genomic RNA [36]. Previously, Suin et al. [36] found a
good correlation between viral RNA load and infectious virus titer
in the brain. Brain samples were homogenised using a tissue
homogenizer (Bullet Blender, Next Advance, New York, USA)
and 5 mm stainless steel beads in 350–1000 ml lysis buffer (RLT
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buffer, as supplied with Qiagen RNeasy kit, with 1% b-
mercaptoethanol). Total RNA was extracted using the Qiagen
RNeasy kit (Qiagen, Hilden, Germany), according to manufac-
turer’s instructions. RNA was quantified with the NanoVue
spectrophotometer (GE Healthcare, Bucks, UK). A CVS-11
standard curve was established for each plate based on serial
dilutions of a well-defined virus stock. Ribosomal 18S or GAPDH
were used as reference genes for standardization. Delta cycle
thresholds (DCt) values were calculated using the following
formula: DCt=Ctref - Ct, with Ctref equal to 45, which is the
number of cycles of this qPCR program.
The fluorescent antigen test (FAT) was performed according to
the Manual of Diagnostic Tests and Vaccines for Terrestrial
Animals (Office International des Epizooties, 2008). Brain smears
were fixed with 75% acetone for 30 min at 220u and incubated
with FITC-coupled anti-nucleocapsid rabbit antibody for 30 min
at 37uC.
Pharmacokinetic study
The plasma and brain disposition upon systemic administration
of the Rab-E8/H7 VHH and its albumin-binding counterpart was
investigated in a pharmacokinetic study. To this end, 48 animals
were treated with a single intraperitoneal injection of 10 mg Rab-
E8/H7 or 5 mg HLE Rab-E8/H7. Three mice were sacrificed per
sampling time point. Immediately before euthanasia, each mice
received a transcardial perfusion with phosphate-buffered saline
(PBS) [37]. Briefly, mice were injected intraperitoneally with a
mixture of xylazine (Rompun 2%, Bayer Healthcare, Kiel,
Germany, 9.9 mg/kg) and ketamine (Ceva, Brussels, Belgium,
100 mg/kg) to induce deep terminal anaesthesia. Upon the
disappearance of the eye lid and motor reflexes, the thorax was
opened to expose the heart. Twenty ml of PBS of 37uC was
injected directly into the left ventricle of the heart at a steady
perfusion rate of 10 ml/min. An incision was made in the right
heart chamber to drain out the blood from the circulatory system.
After perfusion, both brain halves were collected and snap frozen
in dry ice.
One brain halve was homogenized in ice cold PBS supple-
mented with 1 mM phenylmethanesulfonylfluoride (PMSF) and
protease inhibitor cocktail (VWR International) using 5 mm
stainless steel beads in a tissue homogenizer (Bullet Blender, Next
Advance, New York, USA). For homogenization of the brain
samples a fixed volume of 1.25 ml was used (approximately a 1:10
ratio of tissue: lysis buffer). Homogenates were subsequently
centrifuged for 20 min at 13000 g and supernatant was transferred
to a new tube and stored at 280uC until quantification. The total
amount of protein present in the homogenates was determined
using the Bradford method. For the calibration curve a dilution
series of BSA was used ranging from 1.0 to 0.063 mg/ml. 20 ml of
standard and samples (1/30 dilution) was mixed with 300 ml
Bradford Ultra Reagent (Expedeon; CatBFU1L). Absorbance at
595 nm was measured and concentration of samples was
interpolated from the standard curve.
For ELISA analysis, total brain amounts were calculated and
were normalized for a theoretical brain weight of 0.5 g (source
www.mbl.org/atlas170) per mouse brain. A density of 1 g/ml was
assumed to calculate VHH brain concentration [38]. Undiluted
brain lysate or plasma samples that resulted in signals below the
assay’s limit of quantification (0.1 ng/ml) were considered as
missing. Pharmacokinetic parameters were estimated by non-
compartmental analysis (Plasma Model Type 200, sparse sam-
pling) using WinNonLin software version 6.3 (Phoenix Pharsight,
Mountain View, CA).
The average maximum concentration in plasma (Cmax) and
corresponding mean time (tmax) were directly derived from the
plasma concentration-time profiles. The area under the plasma
concentration-time curve from the time of dosing to the time of the
last measurable concentration (AUC(0-t)) was calculated by the
linear trapezoidal rule and extrapolated to infinity (AUCinf) as
AUC(0-t)+Ct/lz, in which lz, the first order rate constant
associated with the terminal elimination phase, was estimated by
linear regression of time versus log concentration. The half-life (t1/
2) of the terminal elimination phase was calculated as ln(2)/lz.
Quantification of anti-rabies VHH in plasma and brain
homogenates
To quantify the amount of anti-rabies VHH in the homoge-
nized brain tissues and plasma, the samples were tested in a virus-
neutralization assay (RFFIT) or in an ELISA using the Platelia
TM Rabies II Kit from Bio-Rad (both as described above). For the
standard curve, a serial 1.7 dilution series of the anti-rabies VHH
ranging from 250 to 0.05 ng/ml in 20% brain matrix was used.
Brain samples were measured at 1/5 dilutions, plasma samples at
dilutions ranging from 1/25 to 1/900, all in duplicate. Samples
(50 ml/well) were transferred to the plate provided by the kit. The
linear range of the standard curve was determined using 4PL
analysis (Graphpad Prism), which ranged from 0.1 to 10 ng/ml.
The assay’s range and accuracy was confirmed with spiked VHH
controls of 1, 2 and 5 ng/ml. Concentrations of unknown samples
were determined by interpolation from the standard curve. For the
plasma samples, the reported concentration was derived from
averaging the values of the different dilutions.
Clinical follow-up
Mice were observed daily for signs of disease throughout the
experiment until maximum 35 days after virus inoculation. Signs
of disease were evaluated as follows: weight loss (0 = absent,
1 = visible), depression (0 = absent, 1 = lower (re)activity), hunched
back (0 = absent, 1 = present), motoric incoordination (0 = absent,
1 = present), rough hair coat (0 = absent, 1 = present), paralysis of
the hind legs (0 = absent, 1 = present) and conjunctivitis (0 = ab-
sent, 1 = present). The cumulative daily clinical score per mouse
was calculated as the sum of the scores for each parameter. Disease
progression was represented by plotting the cumulative daily score
in function of the days post inoculation (DPI). The cumulative
daily score per mouse ranged from 0 (no disease) to 7 (severe
nervous disease). In our experience, mice with a disease score of 6
or more die within one day [35]. Therefore, mice were euthanized
by cervical dislocation when they reached a disease score of $6.
Results were expressed as Kaplan-Meier survival curves. Graph-
Pad Prism was used for statistical analyses of in vivo data.
Differences in survival times were tested using the Log-Rank test
with a Bonferroni post-test, differences in DCt values were tested
using a student t-test after normalization to the house-keeping
gene.
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